Label Changes for:

Atacand (Candesartan Cilexetil) Tablets

April 2013

Changes have been made to the CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – April 2013



  • Atacand is contraindicated in patients who are hypersensitive to candesartan. Do not administer Aliskiren with Atacand in patients with diabetes.